Emerging Markets, U.S. Provide Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher
This article was originally published in PharmAsia News
Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.
You may also be interested in...
Germany’s IQWiG Pans Sanofi’s Lyxumia For Wrong Comparator Choices
Sanofi’s failure to align its comparator selection with that of Germany’s reimbursement authorities has resulted in dismissal of Lyxumia for diabetes type 2, although the company will have an opportunity to challenge the decision.
EU’s IMI, Drug Makers And Universities Join In New R&D Effort
Europe’s latest push to speed up new medicine discovery will see a new European Lead Factory set up under the EU’s Innovative Medicines Initiative, combining a library of up to 500,000 drug candidates from industry and academia and high-throughput screening centers to identify and generate new therapies.
GSK To Downplay Europe Because of Poor Innovation Support, Focuses On U.S. and Japan Instead
GSK CEO Andrew Witty is scathing about the lack of support in Europe for innovation, and the company will now prioritize the U.S., Japan and emerging markets for the development of new products